Literature DB >> 9382958

Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice.

E Zsigmond1, K Kobayashi, K W Tzung, L Li, Y Fuke, L Chan.   

Abstract

Lipoprotein lipase (LPL) is the rate-limiting enzyme for the hydrolysis of triglyceride-rich lipoproteins. We tested the efficacy of adenovirus-mediated gene transfer of LPL as treatment of experimental hyperlipidemias associated with apolipoprotein (apoE) deficiency (apoE-/-) and low-density lipoprotein receptor (LDLr) deficiency (LDLr-/-) in mice. Replication-defective adenovirus containing the human LPL cDNA driven by a cytomegalovirus promoter (Ad.hLPL) efficiently transduced CHO-ldlA7 cells in vitro, inducing in these cells the production of bioactive LPL (73 mU/ml). Intravenous injection of Ad.hLPL (2 x 10(9) pfu) led to high-level expression of hLPL mRNA and LPL activity in the liver (88.3 mU/ml) and in post-heparin plasma (116.1 mU/ml). Overexpression of LPL resulted in marked reductions in total plasma cholesterol (TC; 48%, 43%, 25%) and triglycerides (TTg; 63%, 40%, 70%, p < 0.01) in apoE-/-, LDLr-/-, and wild-type (WT) mice, respectively. Fast protein liquid chromatography (FPLC) fractionation of plasma lipoproteins showed a marked decrease in very-low-density lipoprotein (VLDL)/chylomicron remnant cholesterol (V/CR-C) in apoE-/- (83%), LDLr-/- (84%), and WT mice (58%, p < 0.01). VLDL/chylomicron remnant triglycerides (V/CR-Tg) were virtually eliminated in apoE-/- (92%), LDLr-/- (86%), and WT mice (84%, p < 0.05). No significant changes were detected in LPL activities, plasma lipids, or lipoproteins of mice injected with a control virus, Ad.Luc, containing the luciferase instead of the LPL cDNA. In summary, infusion of Ad.hLPL leads to increased liver and post-heparin plasma LPL activities, significantly reduced TC, TTg, V/CR-C, and V/CR-Tg in WT mice, as well as in mice with apoE and LDLr deficiencies. Adenovirus-mediated LPL gene transfer to the liver is an effective means of reversing many of the lipoprotein abnormalities in apoE- and LDLr-deficient mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9382958     DOI: 10.1089/hum.1997.8.16-1921

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  10 in total

Review 1.  Liver-directed gene therapy for dyslipidemia and diabetes.

Authors:  Kazuhiro Oka; Lawrence Chan
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

Review 2.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

3.  Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism.

Authors:  J D Medh; G L Fry; S L Bowen; S Ruben; H Wong; D A Chappell
Journal:  J Lipid Res       Date:  2000-11       Impact factor: 5.922

Review 4.  Gene therapy for dyslipidemia: clinical prospects.

Authors:  D J Rader; U J Tietge
Journal:  Curr Atheroscler Rep       Date:  1999-07       Impact factor: 5.113

Review 5.  Recent advances in liver-directed gene therapy for dyslipidemia.

Authors:  Kazuhiro Oka; Lawrence Chan
Journal:  Curr Atheroscler Rep       Date:  2002-05       Impact factor: 5.113

6.  Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion.

Authors:  Yan Wang; Viktoria Gusarova; Serena Banfi; Jesper Gromada; Jonathan C Cohen; Helen H Hobbs
Journal:  J Lipid Res       Date:  2015-05-07       Impact factor: 5.922

7.  Overexpression of lipoprotein lipase improves insulin resistance induced by a high-fat diet in transgenic rabbits.

Authors:  S Kitajima; M Morimoto; E Liu; T Koike; Y Higaki; Y Taura; K Mamba; K Itamoto; T Watanabe; K Tsutsumi; N Yamada; J Fan
Journal:  Diabetologia       Date:  2004-06-25       Impact factor: 10.122

8.  Gene therapy for atherosclerosis and atherosclerosis-related diseases.

Authors:  T Pakkanen; S Ylä-Herttuala
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.967

9.  Gene therapy for lipid disorders.

Authors:  Daniel J Rader
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000

10.  Leu452His mutation in lipoprotein lipase gene transfer associated with hypertriglyceridemia in mice in vivo.

Authors:  Kaiyue Sun; Wei Yang; Yanna Huang; Yizhen Wang; Lan Xiang; Jianhua Qi
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.